Reyhan Caliskan1, Hrisi Bahar Tokman1, Yusuf Erzin2, Suat Saribas1, Pelin Yuksel1, Bora Kazim Bolek3, Ecehan Ozge Sevuk4, Mehmet Demirci1, Ozge Yılmazli1, Ozer Akgul1, Fatma Kalayci1, Huseyin Cakan5, Barik Salih6, Kadir Bal2, Bekir Kocazeybek1. 1. Cerrahpasa Faculty of Medicine, Department of Medical Microbiology, Istanbul University, Istanbul, Turkey. 2. Cerrahpasa Faculty of Medicine, Department of Gastroenterology, Istanbul University, Istanbul, Turkey. 3. Medical Laboratory Techniques Program, Vocational School of Health Services, Istanbul Esenyurt University, Istanbul, Turkey. 4. Faculty of Arts and Sciences, Department of Biology, Fatih University, Istanbul, Turkey. 5. Institute of Forensic Sciences,, Department of Microbiology, Istanbul University, Istanbul, Turkey. 6. Faculty of Arts and Sciencs, Department of Biology, Fatih University, Istanbul, Turkey.
Abstract
INTRODUCTION: Antibiotic resistance is the main factor that affects the efficacy of current therapeutic regimens against Helicobacter pylori. This study aimed to determine the rates of resistance to efficacy clarithromycin, amoxicillin, tetracycline, levofloxacin and metronidazole among H. pylori strains isolated from Turkish patients with dyspepsia. METHODS: H. pylori was cultured from corpus and antrum biopsies that were collected from patients with dyspeptic symptoms, and the antimicrobial susceptibility of H. pylori was determined using the E-test (clarithromycin, amoxicillin, tetracycline, metronidazole and levofloxacin) according to the EUCAST breakpoints. Point mutations in the 23S rRNA gene of clarithromycin-resistant strains were investigated using real-time PCR. RESULTS: A total of 98 H. pylori strains were isolated, all of which were susceptible to amoxicillin and tetracycline. Of these strains, 36.7% (36/98) were resistant to clarithromycin, 35.5% (34/98) were resistant to metronidazole, and 29.5% (29/98) were resistant to levofloxacin. Multiple resistance was detected in 19.3% of the isolates. The A2143G and A2144G point mutations in the 23S rRNA-encoding gene were found in all 36 (100%) of the clarithromycin-resistant strains. Additionally, the levofloxacin MIC values increased to 32 mg/L in our H. pylori strains. Finally, among the clarithromycin-resistant strains, 27.2% were resistant to levofloxacin, and 45.4% were resistant to metronidazole. CONCLUSIONS: We conclude that treatment failure after clarithromycin- or levofloxacin-based triple therapy is not surprising and that metronidazole is not a reliable agent for the eradication of H. pylori infection in Turkey.
RCT Entities:
INTRODUCTION: Antibiotic resistance is the main factor that affects the efficacy of current therapeutic regimens against Helicobacter pylori. This study aimed to determine the rates of resistance to efficacy clarithromycin, amoxicillin, tetracycline, levofloxacin and metronidazole among H. pylori strains isolated from Turkish patients with dyspepsia. METHODS:H. pylori was cultured from corpus and antrum biopsies that were collected from patients with dyspeptic symptoms, and the antimicrobial susceptibility of H. pylori was determined using the E-test (clarithromycin, amoxicillin, tetracycline, metronidazole and levofloxacin) according to the EUCAST breakpoints. Point mutations in the 23S rRNA gene of clarithromycin-resistant strains were investigated using real-time PCR. RESULTS: A total of 98 H. pylori strains were isolated, all of which were susceptible to amoxicillin and tetracycline. Of these strains, 36.7% (36/98) were resistant to clarithromycin, 35.5% (34/98) were resistant to metronidazole, and 29.5% (29/98) were resistant to levofloxacin. Multiple resistance was detected in 19.3% of the isolates. The A2143G and A2144G point mutations in the 23S rRNA-encoding gene were found in all 36 (100%) of the clarithromycin-resistant strains. Additionally, the levofloxacin MIC values increased to 32 mg/L in our H. pylori strains. Finally, among the clarithromycin-resistant strains, 27.2% were resistant to levofloxacin, and 45.4% were resistant to metronidazole. CONCLUSIONS: We conclude that treatment failure after clarithromycin- or levofloxacin-based triple therapy is not surprising and that metronidazole is not a reliable agent for the eradication of H. pyloriinfection in Turkey.
Authors: Murat Erkut; Doğan Yusuf Uzun; Neşe Kaklıkkaya; Sami Fidan; Yaşar Yoğun; Arif Mansur Coşar; Esma Akyıldız; Murat Topbaş; Orhan Özgür; Mehmet Arslan Journal: Turk J Gastroenterol Date: 2020-03 Impact factor: 1.852
Authors: Noor Ul Islam; Muhammad Naveed Umar; Ezzat Khan; Fakhria A Al-Joufi; Shaymaa Najm Abed; Muhammad Said; Habib Ullah; Muhammad Iftikhar; Muhammad Zahoor; Farhat Ali Khan Journal: Antibiotics (Basel) Date: 2022-06-13
Authors: I Thung; H Aramin; V Vavinskaya; S Gupta; J Y Park; S E Crowe; M A Valasek Journal: Aliment Pharmacol Ther Date: 2015-12-23 Impact factor: 8.171
Authors: Kevin F Boehnke; Manuel Valdivieso; Alejandro Bussalleu; Rachael Sexton; Kathryn C Thompson; Soledad Osorio; Italo Novoa Reyes; John J Crowley; Laurence H Baker; Chuanwu Xi Journal: Infect Drug Resist Date: 2017-03-10 Impact factor: 4.003
Authors: Alba A Trespalacios-Rangél; William Otero; Azucena Arévalo-Galvis; Raúl A Poutou-Piñales; Emiko Rimbara; David Y Graham Journal: PLoS One Date: 2016-07-25 Impact factor: 3.240